Compounds > pyrrolomycin d
Page last updated: 2024-11-07

pyrrolomycin d

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pyrrolomycin D: from Streptomyces strain SF-2080; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID133780
CHEMBL ID4101922
MeSH IDM0106751

Synonyms (8)

Synonym
antibiotic sf 2080d
(3,5-dichloro-2-hydroxyphenyl)(3,4,5-trichloro-1h-pyrrol-2-yl)methanone
methanone, (3,5-dichloro-2-hydroxyphenyl)(3,4,5-trichloro-1h-pyrrol-2-yl)-
sf 2080d
pyrrolomycin d
81910-07-8
DTXSID90231462
CHEMBL4101922
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID1530241Antibiofilm activity against Staphylococcus aureus isolate 657 at 1.5 ug/ml relative to control2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthetic small molecules as anti-biofilm agents in the struggle against antibiotic resistance.
AID1530238Antibiofilm activity against Staphylococcus aureus ATCC 29213 at 1.5 ug/ml relative to control2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthetic small molecules as anti-biofilm agents in the struggle against antibiotic resistance.
AID1471337Inhibition of biofilm formation in Staphylococcus aureus ATCC 29213 at 1.5 ug/ml after 24 hrs by MTT assay2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms.
AID1471344Inhibition of biofilm formation in Staphylococcus epidermidis RP62A at 1.5 ug/ml after 24 hrs by MTT assay2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms.
AID1471340Inhibition of biofilm formation in Staphylococcus aureus ATCC 25923 at 1.5 ug/ml after 24 hrs by MTT assay2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms.
AID1530239Antibiofilm activity against Staphylococcus epidermidis DSM 3269 at 1.5 ug/ml relative to control2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthetic small molecules as anti-biofilm agents in the struggle against antibiotic resistance.
AID1471342Inhibition of biofilm formation in Staphylococcus aureus ATCC 702 at 1.5 ug/ml after 24 hrs by MTT assay2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms.
AID1471343Inhibition of biofilm formation in Staphylococcus epidermidis DSM 3269 at 1.5 ug/ml after 24 hrs by MTT assay2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms.
AID1530237Antibiofilm activity against Staphylococcus aureus ATCC 25923 at 1.5 ug/ml relative to control2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthetic small molecules as anti-biofilm agents in the struggle against antibiotic resistance.
AID1530240Antibiofilm activity against Staphylococcus epidermidis RP62A at 1.5 ug/ml relative to control2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthetic small molecules as anti-biofilm agents in the struggle against antibiotic resistance.
AID1471341Inhibition of biofilm formation in Staphylococcus aureus ATCC 657 at 1.5 ug/ml after 24 hrs by MTT assay2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms.
AID1530242Antibiofilm activity against Staphylococcus aureus isolate 702 at 1.5 ug/ml relative to control2019European journal of medicinal chemistry, Jan-01, Volume: 161Synthetic small molecules as anti-biofilm agents in the struggle against antibiotic resistance.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (66.67)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.38 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
reserpine
Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.		2.1510alkaloid ester;
methyl ester;
yohimban alkaloid		adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		2.8840pyrrole;
secondary amine
deoxyglucose
Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.		1.9610
tazobactam
Tazobactam: A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria.. tazobactam : A member of the class of penicillanic acids that is sulbactam in which one of the exocyclic methyl hydrogens is replaced by a 1,2,3-triazol-1-yl group; used (in the form of its sodium salt) in combination with ceftolozane sulfate for treatment of complicated intra-abdominal infections and complicated urinary tract infections.		2.1510penicillanic acids;
triazoles		antiinfective agent;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor
pyrrolomycin a
pyrrolomycin A: chlorinated nitropyrrole from Actinomycetes strain SF-2080; structure given in first source. pyrrolomycin A : A member of the class of pyrroles that is 1H-pyrrole which is substituted by chloro groups at positions 2 and 3 and by a nitro group position 4. It is the simplest member of the pyrrolomycins, a family of natural products found in several species of the Streptomyces genus. The compound is active against Gram-positive and Gram-negative bacteria and some genera of fungi.		1.9610antibiotic antifungal agent;
C-nitro compound;
organochlorine compound;
pyrroles		antibacterial agent;
bacterial metabolite
pyrrolomycin c
pyrrolomycin C: from Streptomyces strain SF-2080; structure given in first source		2.8840
phenylalanine arginine beta-naphthylamide
phenylalanine arginine beta-naphthylamide: a drug efflux pump inhibitor; structure in first source		2.1510peptide
arachidonic acid
icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.		1.9610icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid		Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite
1-(1-naphthylmethyl)piperazine
[no description available]		2.1510
capsaicin
ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.		2.1510capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
oroidin
oroidin: from marine sponges of the genus Agelas; structure in first source		3.3110pyrroles;
secondary carboxamide		metabolite
nxl 104
avibactam sodium : An organic sodium salt that is the monosodium salt of avibactam. Used in combination with ceftazidime pentahydrate for the treatment of complicated urinary tract infections including pyelonephritis.		2.1510organic sodium saltantibacterial drug;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor
rpx7009
RPX7009: a beta-lactamase inhibitor; structure in first source		2.1510
ConditionIndicatedRelationship StrengthStudiesTrials
Infections, Pseudomonas
[description not available]		02.1510
Cronobacter Infections
[description not available]		02.1510
Enterobacteriaceae Infections
Infections with bacteria of the family ENTEROBACTERIACEAE.		02.1510
Pseudomonas Infections
Infections with bacteria of the genus PSEUDOMONAS.		02.1510
Extravascular Hemolysis
[description not available]		01.9610
Hemolysis
The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.		01.9610